Stock Price
164.18
Daily Change
2.80 1.74%
Monthly
-17.36%
Yearly
-38.95%
Q1 Forecast
161.08



Peers Price Chg Day Year Date
Avita Medical 1.13 0.02 1.80% -61.03% Mar/25
Ansell 28.88 0.76 2.70% -15.36% Mar/25
Cochlear 164.18 2.80 1.74% -38.95% Mar/25
CSL 141.29 1.90 1.36% -44.14% Mar/25
Fisher Paykel Healthcare 37.19 1.01 2.79% 7.49% Mar/25
Healius 0.57 0.03 5.19% -56.64% Mar/25
Integral Diagnostics 2.37 0.01 0.42% 2.60% Mar/25
Mesoblast 2.22 0.16 7.77% 0.91% Mar/25
Monash IVF 0.66 0.01 0.77% -39.35% Mar/25
Mayne Pharma 2.30 0.05 2.22% -68.19% Mar/25

Indexes Price Day Year Date
ASX200 8505 125.75 1.50% 6.33% Mar/25
ASX All Share 8742 170.46 1.99% 6.28% Mar/25
AU50 8350 135.10 1.64% 6.68% Mar/25

Cochlear traded at 164.18 this Wednesday March 25th, increasing 2.80 or 1.74 percent since the previous trading session. Looking back, over the last four weeks, Cochlear gained 17.36 percent. Over the last 12 months, its price fell by 38.95 percent. Looking ahead, we forecast Cochlear to be priced at 161.08 by the end of this quarter and at 150.91 in one year, according to Trading Economics global macro models projections and analysts expectations.

Cochlear Limited is an Australian-based company, which provides implantable hearing solutions. The Company designs and offers products and accessories for adults or children. The Company operates through three geographical segments: Americas, EMEA and Asia Pacific. Its products offer various ways to hear, such as automatically adjusting hearing to different environments and streaming sound from a smartphone. It provides various products, including Nucleus sound processors, Smart bimodal hearing solution, Nucleus implants, Nucleus implant reliability, Baha sound processors, Baha implants, Baha Softband, SoundArc. The Company’s accessories include True Wireless devices, Nucleus water-safe accessories, Keeping device in place.